Abbott Laboratories (ABT)

NYSE: ABT · IEX Real-Time Price · USD
110.55
-1.48 (-1.32%)
Aug 17, 2022 4:03 PM EDT - Market closed
-1.32%
Market Cap 193.60B
Revenue (ttm) 45.55B
Net Income (ttm) 8.55B
Shares Out 1.75B
EPS (ttm) 4.79
PE Ratio 23.08
Forward PE 22.52
Dividend $1.86 (1.68%)
Ex-Dividend Date Jul 14, 2022
Volume 3,052,893
Open 111.63
Previous Close 112.03
Day's Range 110.37 - 112.13
52-Week Range 101.24 - 142.60
Beta 0.70
Analysts Buy
Price Target 130.47 (+18.0%)
Earnings Date Jul 20, 2022

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipi... [Read more...]

Industry Health Care Equipment & Supplies
Founded 1888
CEO Robert Ford
Employees 113,000
Stock Exchange NYSE
Ticker Symbol ABT
Full Company Profile

Financial Performance

In 2021, ABT's revenue was $43.08 billion, an increase of 24.47% compared to the previous year's $34.61 billion. Earnings were $7.07 billion, an increase of 57.31%.

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 130.47, which is an increase of 18.02% from the latest price.

Price Target
$130.47
(18.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Should Dividend Investors Add This Stock to Their Portfolios?

This Dividend King pays shareholders a market-beating dividend.

Abbott to add 1,000 jobs in $450 million Irish investment

U.S. healthcare company Abbott Laboratories plans to hire 1,000 more people in Ireland in one of the biggest job announcements this year in the country's booming multinational sector, state investment a...

2 Healthcare Stocks That Could Help Set You Up for Life

Whether your goal is building generational wealth or simply achieving financial independence, buying these two stocks could be worth your while.

Other symbols: HUM

2 Dividend Kings That Have Hiked Their Payouts by More Than 50% in 5 Years

These companies aren't stingy when it comes to making rate hikes.

Other symbols: AWR

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Inte...

The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care Researc...

Should You Really Care About This Company's Short-Term Success?

Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.

Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals

Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health Collaboration will create a seaml...

Final Trades: TJX, Qualcomm, Abbott Labs & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: QCOMTJXAPD

3 Dividend Aristocrats to Buy in August

These stocks have reliable dividends and strong underlying businesses.

Other symbols: ABBVPEP

7 Blue-Chip Stocks to Buy Before the Bull Market Returns

The bear market is firmly in place so long as the economy worsens. The incoming recession is a necessary headwind.

Other symbols: CRMIBMJNJMDTRYSTX

Is Abbott Laboratories a Buy?

This stock rewards investors who have patience.

7 Large-Cap Stocks to Buy on the Dip

Following this year's sell-off, seasoned investors are increasingly hunting for large-cap stocks to buy on the dip. For instance, the S&P 500 index and Dow Jones Industrial Average have lost 185 and 13%...

Other symbols: COSTDHRILCVLINNVDA

Why a Product Recall Won't Change This Company's Prospects

This company's business won't fail that easily.

2 Surefire Dividend Stocks That Are Laughing Off Inflation

Their dividends tend to grow much faster than the inflation rate in the long run.

Other symbols: COST

Is Abbott Laboratories stock a ‘buy' after market-beating Q2 results?

Abbott Laboratories (NYSE: ABT) down more than 20% for the year is an opportunity to buy a quality name at a deep discount, says Brenda Vingiello. She's the Chief Investment Officer at Sand Hill Global ...

Final Trades: Boeing, Invitation Homes, Abbott Labs & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: BAINVHWSO

Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up

Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.

Abbott is now aiming to recover the baby-formula market share that it lost

Abbott Laboratories ABT, -1.35% is focused on recovering its position in the baby-formula market in the U.S. following the recall that required the intervention of the Biden administration to ensure tha...

Abbott earnings top estimates as baby formula losses offset by COVID test sales

Yahoo Finance medical reporter Anjalee Khemlani breaks down second-quarter earnings for Abbott Laboratories.

Abbott Laboratories (ABT) Stock Slides Despite Q2 Earnings Beat

Abbott Laboratories (ABT) stock is falling on Wednesday despite posting a positive earnings report for the second quarter of 2022. The post Abbott Laboratories (ABT) Stock Slides Despite Q2 Earnings Bea...

Abbott (ABT) Q2 Earnings and Revenues Top Estimates

Abbott (ABT) delivered earnings and revenue surprises of 31.19% and 8.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Abbott Lifts Annual Profit Guidance On Higher COVID-19 Test Sales

Abbott Laboratories (NYSE: ABT) has reported Q2 FY22 adjusted EPS of $1.43, up 22.2% Y/Y, better than the consensus of $1.12. Q2 sales of $11.3 billion increased 10.1% on a reported basis and 14.3% on a...

What's Going On With Abbott Stock Today?

Abbott Laboratories (NYSE: ABT) shares are trading lower Wednesday after the company reported financial results. Abbott said second-quarter revenue increased 10.1% year-over-year to $11.3 billion, which...

Abbott Laboratories shares fall in premarket despite second-quarter earnings beat

Shares of Abbott Laboratories ABT, +2.72% fell 2.85% to $106.8 in premarket trading Wednesday although the company beat second-quarter earnings and sales estimates, fueled by sales of its COVID-19 tests...

Abbott Laboratories Posts Better-Than-Expected Q2 Sales, Earnings

Abbott Laboratories on Wednesday topped estimates for second-quarter sales and earnings and guided higher for the full year. The post Abbott Laboratories Posts Better-Than-Expected Q2 Sales, Earnings ap...